Science Corporation announced a $400 million Series D on November 17 to expand the European rollout of PRIMA, its retinal implant for people with severe central vision loss. The financing also backs preparations for a US launch, which still requires FDA approval.
Commercial use remains at an early stage: Science has implanted the commercial version in two patients in Germany, with dozens more being scheduled, according to Investing.com’s account of Bloomberg’s reporting. That report put Science’s valuation at $3.5 billion.
PRIMA pairs a chip placed beneath the retina with glasses that capture images and project them onto the implant using near-infrared light. The chip stimulates surviving retinal cells, helping patients with advanced geographic atrophy caused by age-related macular degeneration regain some central vision, including the ability to read letters and words.
Science closed a $230 million Series C on March 5, before launching PRIMA commercially in Europe on July 22. Khosla Ventures, Tenet Healthcare and the Ackman Oxman Institute participated in the new round. Science said the proceeds will also expand manufacturing and research infrastructure and fund its separate neural-interface program using engineered neurons.
In an October 5 update, Science reported that 14 of 18 patients assessed at three years could read at least 15 additional letters on an eye chart. The original trial implanted 38 patients and had no randomized control group. Its published 12-month results recorded 26 serious adverse events in 19 participants, mostly soon after surgery. Science reported no new safety signal between months 12 and 36.
Science is seeking US approval through the FDA’s Humanitarian Device Exemption pathway. Chief Executive Max Hodak expects commercial availability in the first half of 2027, according to the Bloomberg interview recounted by Investing.com.